Potential conflict of interest: F.N. is consultant for Roche and MSD, is advising Gilead, Janssen, MSD, Novartis and Boehringer Ingelheim, and has received unrestricted research grants from Roche, Gilead and Novartis.
Is genotype 3 of the hepatitis C virus the new villain?
Article first published online: 14 APR 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 59, Issue 6, pages 2403–2412, June 2014
How to Cite
Goossens, N. and Negro, F. (2014), Is genotype 3 of the hepatitis C virus the new villain?. Hepatology, 59: 2403–2412. doi: 10.1002/hep.26905
The authors' quoted work is supported by Swiss National Science Foundation grant numbers 314730-130498 and 314730-146991 and by the Foundation for Liver and Gut Studies, Geneva, Switzerland.
- Issue published online: 28 MAY 2014
- Article first published online: 14 APR 2014
- Accepted manuscript online: 24 OCT 2013 04:50AM EST
- Manuscript Accepted: 18 OCT 2013
- Manuscript Received: 23 MAY 2013
Genotype 3 of the hepatitis C virus (HCV) has been long considered an easy-to-treat infection, with higher cure rates (∼70%) than other viral genotypes with the standard combination of pegylated interferon-α and ribavirin. However, the relative insensitivity of this genotype to most protease inhibitors and the recent unexpected data on decreased effectiveness of sofosbuvir have raised questions on how to achieve universal cure, a goal that seems reasonable for other genotypes. In addition, increasing clinical and experimental data show that HCV genotype 3 may be associated not only with severe steatosis, but also with accelerated fibrosis progression rate and increased oncogenesis. Conclusion: Currently available data suggest that we should increase our efforts to understand the virology and pathogenesis of HCV genotype 3, aiming at better and more potent, genotype-targeted treatments. (Hepatology 2014;59:2403–2412)